China's State Drug Administration approves clinical trial application for Skyland Bio TJM2
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Tianyuan Biotech (Shanghai) LimitedCompany(http://("Tianyuan Bio") announced that China's NationalPharmaceutical(http://Regulatory Authority has approved the tJM2 ClinicalTesting(http://applicationTJM2 is developed by Skycreatures or will benefit from the treatment of rheumatoid arthritis (RA) patientsTJM2 is a humanogenized IgG1 antibody for neutralizing granulocyte macrophage concentration stimulator (GM-CSF), and under the key role of GM-CSF, TJM2 has great potential in treating autoimmune and inflammatory diseasesTJM2 is thehttp://
firstnew drug (http:// candidate drug (http:// in the global (http:// pipeline of natural sciences' global independent innovation products Prior to that, Skyfall Bio had conducted Phase I clinical trials of TJM2 in the United States (NCT03794180) Based on the success of the trial, Tianyuan Bio submitted a clinical trial application for rheumatoid arthritis disease to The State Drug Administration of China in late August this year and was approved on November 8, a Phase I trial in China designed to assess the safety, tolerance, pharmacokinetics, pharmacodynamics and immunoogenicproperties of TJM2 in patients with rheumatoid arthritis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
